EXPERIMENTAL IMMUNOTHERAPY CLINICAL TRIAL NOW ACCEPTING VOLUNTEERS WITH METASTATIC COLORECTAL CANCER IN PHOENIX, AZ

METASTATIC COLORECTAL CANCER PATIENTS:

  1. ARE YOU PROGRESSING AFTER RECEIVING TWO TYPES OF CHEMOTHERAPY?
  2. HAVE YOU BEEN RECOMMENDED FOR STIVARGA® (REGORAFENIB) OR LONSURF® (TAS-103) TREATMENT?
  3. ARE YOU STILL IN RELATIVELY GOOD HEALTH DESPITE THE CANCER?
  4. ARE YOU CONSIDERING VOLUNTEERING FOR A CLINICAL TRIAL?

IF YOU ANSWERED YES TO THESE QUESTIONS, YOU MAY BE ELIGIBLE TO PARTICIPATE IN A CANCER VACCINE IMMUNOTHERAPY CLINICAL TRIAL.

Register Here

Clinical Trial Title:

Increased Frequency of AlloStim® Immunotherapy Dosing in Combination with Cryoablation in Metastatic Colorectal Cancer

STUDY INFORMATION: This clinical trial is designed to test the effectiveness and safety of an experimental immunotherapy cancer vaccine drug in patients with metastatic colorectal cancer. The drug is experimental and has not been approved by the US FDA. This trial is not designed with a control arm, meaning after enrollment all patients will be scheduled to receive the experimental drug and not a placebo. Patients are placed sequentially in dosing cohorts that vary the frequencies of study drug administration. The different dosing cohorts may have different outcomes (good or bad). It is not known whether any particular cohort is better or worse than the others being tested.

i

Clinical Trial Type

Phase IIb, open label

Sponsor

Immunovative Therapies, Ltd. (Jerusalem, Israel)

Institution

Banner-MD Anderson Medical Center

Principal Investigator

Madappa N. Kundranda, M.D., Ph.D.

Location

Phoenix, Arizona

NCI Trial ID

#: NCT02380443

To be screened for eligibility for no obligation or cost:

Register Here